Business Context and Reporting Period
Liquidia Corporation (LQDA) is a biopharmaceutical company focused on respiratory and vascular diseases, specifically pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company reported for the fiscal quarter ended June 30, 2026. Its primary revenue driver is YUTREPIA (treprostinil) inhalation powder, which received FDA approval in May 2025 and began commercialization in June 2025. The company also generates service revenue through a promotion agreement with Sandoz regarding generic treprostinil injection.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $171.7 million | $8.8 million | $304.5 million | $12.0 million |
| Net Income (Loss) | $74.7 million | ($41.6 million) | $127.6 million | ($79.9 million) |
| Operating Income (Loss) | $85.5 million | ($37.5 million) | $147.0 million | ($72.9 million) |
| Operating Margin | 49.8% | (424.5%) | 48.3% | (610.0%) |
| Cash and Equivalents | $284.2 million (as of June 30, 2026) | N/A | ||
| Long-Term Debt | $176.1 million (Total) | N/A | ||
| Stockholders' Equity | $195.1 million | N/A |
Notes: The company achieved profitability in Q2 2026, reversing a net loss in the prior year period. Operating cash flow for the six months ended June 30, 2026, was $133.2 million, compared to a use of $70.2 million in the prior year period.
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased by 1,843% in Q2 2026 compared to Q2 2025, driven almost entirely by YUTREPIA product sales, which grew from $6.5 million to $170.4 million. This reflects the commercial launch of YUTREPIA in June 2025.
- Profitability Turnaround: The company transitioned from a net loss of $41.6 million in Q2 2025 to a net income of $74.7 million in Q2 2026. Operating income swung from a loss of $37.5 million to a profit of $85.5 million.
- Expense Growth: Selling, general, and administrative (SG&A) expenses increased by 48% year-over-year in Q2 2026 to $57.4 million, primarily due to increased personnel costs and commercialization expenses for YUTREPIA. Research and development (R&D) expenses rose 185% to $17.2 million, driven by the L606 program and a $1.0 million development milestone.
- Balance Sheet Strength: Cash and cash equivalents increased from $190.7 million at year-end 2025 to $284.2 million at June 30, 2026, bolstered by strong operating cash flows.
Guidance, Outlook, Risks, and Contingencies
Outlook and Liquidity: Management believes it has sufficient cash and cash equivalents to meet financial obligations and minimum cash covenants for at least the next twelve months. The company expects to continue incurring significant expenses to commercialize YUTREPIA and advance the L606 product candidate.
Key Risks and Contingencies:
- Patent Litigation: United Therapeutics has initiated multiple lawsuits alleging patent infringement and trade secret misappropriation. In the '327 Patent Litigation, United Therapeutics seeks injunctive relief that could require YUTREPIA to be removed from the market. A trial was held in June 2025, and a decision is pending. An adverse outcome could materially disrupt business operations.
- Supply Chain Constraints: The company relies on single-source suppliers for the active pharmaceutical ingredient (API), encapsulation, and packaging of YUTREPIA. Additionally, the availability of the CADD-MS 3 infusion pump required for Treprostinil Injection is constrained as the manufacturer no longer supports it, potentially limiting service revenue.
- Debt Covenants: The company has a revenue interest financing agreement with HealthCare Royalty Partners IV, L.P. (HCR) that requires maintaining a minimum cash balance of $15.0 million. Failure to meet covenants could trigger acceleration of debt payments.
- Regulatory and Competitive Risks: The company faces competition from United Therapeutics' Tyvaso DPI and other emerging therapies. Regulatory approval for new indications or product candidates (like L606) is not guaranteed.
Investor Verification Checklist
- Legal Proceedings Status: Verify the outcome of the pending '327 Patent Litigation trial decision, as an injunction could halt YUTREPIA sales.
- YUTREPIA Sales Trajectory: Monitor quarterly product sales volumes and gross-to-net adjustments to assess the sustainability of the revenue growth.
- Debt Covenant Compliance: Confirm continued adherence to the $15.0 million minimum cash balance covenant under the HCR Agreement.
- Supply Chain Resilience: Assess the status of alternative infusion pump solutions for Treprostinil Injection and the stability of single-source suppliers for YUTREPIA.
- L606 Development: Track progress and data release timelines for the L606 pivotal clinical trials to evaluate future pipeline value.